Baader Bank Aktiengesellschaft Invests $1.37 Million in Qiagen N.V. $QGEN

Baader Bank Aktiengesellschaft purchased a new position in shares of Qiagen N.V. (NYSE:QGEN) in the first quarter, Holdings Channel reports. The fund purchased 34,171 shares of the company’s stock, valued at approximately $1,368,000.

Several other institutional investors have also recently made changes to their positions in the business. Allworth Financial LP boosted its stake in shares of Qiagen by 23.2% during the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after acquiring an additional 256 shares in the last quarter. Banque Cantonale Vaudoise lifted its stake in Qiagen by 1.8% in the 4th quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock worth $747,000 after purchasing an additional 290 shares in the last quarter. Commerce Bank grew its holdings in shares of Qiagen by 4.9% in the fourth quarter. Commerce Bank now owns 6,725 shares of the company’s stock valued at $302,000 after purchasing an additional 314 shares during the period. Truist Financial Corp raised its position in shares of Qiagen by 4.1% during the 4th quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock valued at $379,000 after buying an additional 331 shares during the period. Finally, Private Advisor Group LLC raised its holdings in Qiagen by 7.1% in the 3rd quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock valued at $256,000 after buying an additional 378 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on QGEN. Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Barclays set a $38.00 price objective on shares of Qiagen and gave the company an “equal weight” rating in a research note on Wednesday, April 29th. JPMorgan Chase & Co. dropped their price objective on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, TD Cowen reissued a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Qiagen has a consensus rating of “Hold” and a consensus target price of $43.34.

Qiagen Trading Down 1.6%

NYSE QGEN opened at $40.50 on Tuesday. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. Qiagen N.V. has a 52 week low of $32.53 and a 52 week high of $57.81. The stock has a market capitalization of $8.35 billion, a PE ratio of 21.15, a price-to-earnings-growth ratio of 4.11 and a beta of 0.64. The firm has a 50 day moving average of $37.50 and a two-hundred day moving average of $42.28.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.54. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The business had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. During the same period last year, the business earned $0.56 EPS. As a group, research analysts expect that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were issued a $0.35 dividend. This represents a yield of 90.0%. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s dividend payout ratio is currently 18.32%.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.